Aprea Therapeutics Inc (APRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.91M
Last updated: Nov 17, 2026 at 11:02 AM ET
Aprea Therapeutics Inc (APRE) Financials: Revenue, Profit and Cash Flow
Aprea Therapeutics reported revenue of $285.76K for the fiscal year ended Dec 31, 2025, down 81.0% from the year before. That year, net income was -$12.60M with a net margin of -4409.2%, operating cash flow was -$12.89M and free cash flow was -$12.89M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.81M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $285.76K | -81.0% | 100.0% | -4631.1% | -4409.2% |
| Dec 2024 | $1.50M | +157.6% | 100.0% | -953.0% | -862.4% |
| Dec 2023 | $583.23K | N/A | 100.0% | -2652.8% | -2449.6% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2013 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $285.76K | $1.50M | $583.23K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $7.93K | $0 |
| Gross profit | $285.76K | $1.50M | $583.23K | $0 | $0 | $0 | $0 | $0 | -$7.93K | $0 |
| Research and development | $7.04M | $9.36M | $7.63M | $92.42M | $23.90M | $37.88M | $20.95M | $14.19M | $13.39M | $0 |
| Operating income | -$13.23M | -$14.32M | -$15.47M | -$113.39M | -$37.45M | -$52.81M | -$29.54M | -$16.49M | -$15.85M | -$246.49K |
| Net income | -$12.60M | -$12.96M | -$14.29M | -$112.66M | -$37.13M | -$53.48M | -$28.06M | -$15.53M | -$15.19M | -$436.21K |
| EBITDA | -$13.23M | -$14.23M | N/A | -$112.92M | -$36.86M | N/A | -$28.05M | -$15.52M | -$15.18M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.34K | $1.85K | $118.11K | $162.46K | $205.82K | $354.62K | $561.57K | $380.57K | $14.07K |
| Gross profit | $0 | $0 | $0 | $3.34K | $1.85K | $118.11K | $162.46K | $205.82K | $354.62K | $561.57K | $380.57K | $14.07K |
| Operating income | -$5.17M | -$4.03M | -$3.43M | -$2.64M | -$3.12M | -$3.39M | -$4.09M | -$3.23M | -$4.10M | -$3.85M | -$3.15M | -$3.67M |
| Net income | -$4.81M | -$3.59M | -$3.29M | -$2.46M | -$2.97M | -$3.24M | -$3.93M | -$2.89M | -$3.78M | -$3.47M | -$2.81M | -$3.44M |
Balance Sheet
As of Dec 2025, cash and equivalents of $14.60M were 91.7% of total assets of $15.93M, against total liabilities of $2.76M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.93M | $23.98M | $22.65M | $30.16M | $56.82M | $92.81M | $133.61M | $66.02M | $24.76M | N/A |
| Current assets | $15.56M | $23.58M | $22.52M | $30.15M | $56.58M | $92.42M | $133.04M | $66.00M | $24.73M | N/A |
| Cash and equivalents | $14.60M | $22.85M | $21.61M | $28.79M | $53.08M | $89.02M | $130.09M | $65.68M | $24.40M | N/A |
| Total liabilities | $2.76M | $3.36M | $4.39M | $3.20M | $7.32M | $15.41M | $9.36M | $4.87M | $60.53M | $5.70M |
| Short-term debt | N/A | N/A | N/A | N/A | $190.47K | $256.31K | $242.33K | $0 | $0 | $1.48M |
| Shareholder equity | $12.44M | $19.31M | $16.95M | $25.64M | $49.51M | $77.40M | $124.24M | -$51.44M | -$35.77M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $38.81M | $42.29M | $47.61M | $15.93M | $14.32M | $17.31M | $20.22M | $23.98M | $26.89M | $29.96M | $33.20M | $22.65M |
| Total liabilities | $3.97M | $3.09M | $5.30M | $3.49M | $2.68M | $3.17M | $3.36M | $4.67M | $3.64M | $3.09M | $2.97M | $4.39M |
| Cash and equivalents | $37.85M | $41.23M | $46.47M | $14.60M | $13.72M | $16.53M | $19.28M | $22.85M | $26.25M | $28.69M | $32.37M | $21.61M |
| Shareholder equity | $34.11M | $38.47M | $41.59M | $12.44M | $10.91M | $13.41M | $15.55M | $19.31M | $21.95M | $25.56M | $28.92M | $18.26M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.89M | -$13.56M | -$12.18M | -$25.01M | -$37.69M | -$41.80M | -$26.71M | -$15.25M | -$14.00M |
| Capital expenditures | $0 | $15.48K | $93.09K | $0 | $0 | $25.71K | $30.90K | $3.70K | $3.70K |
| Free cash flow | -$12.89M | -$13.57M | -$12.27M | -$25.01M | -$37.69M | -$41.83M | -$26.74M | -$15.25M | -$14.01M |
| Share repurchases | $407.46K | $1.32M | $648.93K | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | $0 | -$15.48K | -$93.09K | $0 | $0 | -$25.71K | -$30.90K | -$3.70K | -$3.70K |
| Financing cash flow | $4.64M | $14.82M | $5.14M | $682.97K | $1.75M | $150.95K | $92.58M | $56.37M | $23.34M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.73M | -$3.28M | -$2.76M | -$2.96M | -$3.17M | -$3.13M | -$3.63M | -$3.51M | -$2.47M | -$3.64M | -$3.94M | -$3.74M |
| Capital expenditures | $1 | N/A | $0 | $0 | N/A | $0 | $0 | N/A | $209 | $7.50K | $7.98K | $7.15K |
| Free cash flow | -$3.73M | N/A | -$2.76M | -$2.96M | N/A | -$3.13M | -$3.63M | N/A | -$2.47M | -$3.65M | -$3.94M | -$3.75M |
Frequently Asked Questions About APRE
What is Aprea Therapeutics' annual revenue?
Aprea Therapeutics reported revenue of $285.76K for the fiscal year ended Dec 31, 2025.
How fast is Aprea Therapeutics' revenue growing?
Revenue was down 81.0% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Aprea Therapeutics profitable?
No. Aprea Therapeutics reported net income of -$12.60M for the fiscal year ended Dec 31, 2025, with a net margin of -4409.2%.
How much free cash flow does APRE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.89M minus capital expenditures of $0 produced free cash flow of -$12.89M.
How much debt does Aprea Therapeutics have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $14.60M.
APRE pages: Overview, Earnings, Forecast, Financials, Competitors